Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III sorafenib plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in unresectable stage III or IV melanoma
2005-000941-12Phase 3Completed
- Sponsor
- Onyx Pharmaceuticals
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Sorafenib + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-000941-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000941-12.